Alterome Therapeutics secures $35 million in Series A funding
Alterome Therapeutics is a targeted therapy developer focused on developing biopharmaceuticals for the treatment of cancer-specific targeted therapies that address oncogenic drivers. Alterome Therapeutics announced the completion of over $35 million in Series A financing, co-led by Colt Ventures and OrbiMed, with participation from Nextech Invest, Vida Ventures and Boxer Capital. This article is reproduced […]
Alterome Therapeutics secures $35 million in Series A funding Read More »